%0 Journal Article
%A López-Cortés, Luis F
%A Viciana, Pompeyo
%A Girón-González, José A
%A Romero-Palacios, Alberto
%A Márquez-Solero, Manuel
%A Martinez-Perez, Maria A
%A López-Ruz, Miguel A
%A Torre-Lima, Javier de la
%A Téllez-Pérez, Francisco
%A Delgado-Fernández, Marcial
%A Garcia-Lázaro, Milagros
%A Lozano, Fernando
%A Mohamed-Balghata, Mohamed O
%T Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population.
%D 2014
%U http://hdl.handle.net/10668/1629
%X Etravirine (ETV) is recommended in combination with a boosted protease inhibitor plus an optimized background regimen for salvage therapy, but there is limited experience with its use in combination with two nucleos(t)ide reverse-transcriptase inhibitors (NRTIs). This multicenter study aimed to assess the efficacy of this combination in two scenarios: group A) subjects without virologic failure on or no experience with non-nucleoside reverse-transcriptase inhibitors (NNRTIs) switched due to adverse events and group B) subjects switched after a virologic failure on an efavirenz- or nevirapine-based regimen. The primary endpoint was efficacy at 52 weeks analysed by intention-to-treat. Virologic failure was defined as the inability to suppress plasma HIV-RNA to <50 copies/mL after 24 weeks on treatment, or a confirmed viral load >200 copies/mL in patients who had previously achieved a viral suppression or had an undetectable viral load at inclusion. Two hundred eighty seven patients were included. Treatment efficacy rates in group A and B were 88.0% (CI95, 83.9-92.1%) and 77.4% (CI95, 65.0-89.7%), respectively; the rates reached 97.2% (CI95, 95.1-99.3%) and 90.5% (CI95, 81.7-99.3), by on-treatment analysis. The once-a-day ETV treatment was as effective as the twice daily dosing regimen. Grade 1-2 adverse events were observed motivating a treatment switch in 4.2% of the subjects. In conclusion, ETV (once- or twice daily) plus two analogs is a suitable, well-tolerated combination both as a switching strategy and after failure with first generation NNRTIs, ensuring full drug activity.TRIAL REGISTRATIONClinicalTrials.gov NCT01437241.
%K Etravirina
%K Piridazinas
%K Inhibidores de Proteasas
%K Estudios Multicéntricos como Asunto
%K Seropositividad para VIH
%K Fármacos Anti-VIH
%K Humanos
%K Inhibidores de la Proteasa VIH
%K Inhibidores de Transcriptasa Inversa
%~